A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)

NCT06584916 · Completed

Last updated 2026-07-12

This trial tests whether the medication orforglipron helps people with obesity or overweight maintain weight loss they have already achieved.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 376 people

Who can join Ages 18+ · all sexes

Timeline Started 2024-09 · est. completion 2025-11

Where 29 sites · Puerto Rico, United States

What this study is testing ClinicalTrials.gov NCT06584916 ↗

Description as written by the study sponsor.

The main purpose of this study is to evaluate the efficacy and safety of orforglipron on maintenance of body weight reduction in participants who previously completed treatment with injectable tirzepatide (Zepbound) or injectable semaglutide (Wegovy) in the SURMOUNT-5 trial (NCT05822830).

Treatments tested

Orforglipron Drug

Administered orally
Placebo Drug

Administered orally

Main thing measured	Percent Maintenance of Body Weight Reduction Achieved in SURMOUNT-5
Sponsor	Eli Lilly and Company
Conditions studied	Obesity, Overweight
GLP-1 drugs	orforglipron

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06584916 ↗